Beam Therapeutics Inc. stock is up 19.27% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 6 Unusual Options Trades, there were 1 PUT, 5 CALLs. 0% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|20 Oct 16:18||19 Jan, 2024||25.00||271|
|31 Oct 17:09||15 Dec, 2023||20.00||61|
|03 Nov 17:20||16 Feb, 2024||25.00||251|
|07 Nov 15:24||17 May, 2024||30.00||504|
|21 Nov 14:53||16 Feb, 2024||30.00||199|
|21 Nov 15:48||16 Feb, 2024||30.00||199|
Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.